2017
Progress in the Treatment of Hodgkin’s Lymphoma
Longo DL, DeVita VT. Progress in the Treatment of Hodgkin’s Lymphoma. New England Journal Of Medicine 2017, 378: 392-394. PMID: 29224505, DOI: 10.1056/nejme1715141.Peer-Reviewed Original Research
2014
Treatment of Hodgkin Lymphoma: A 50-Year Perspective
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin Lymphoma: A 50-Year Perspective. Journal Of Clinical Oncology 2014, 32: 163-168. PMID: 24441526, DOI: 10.1200/jco.2013.53.1194.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinClinical Trials as TopicCyclophosphamideDacarbazineDisease-Free SurvivalDoxorubicinEtoposideEuropeHistory, 20th CenturyHodgkin DiseaseHumansMechlorethamineNeoplasm StagingPositron-Emission TomographyPrednisoneProcarbazineSurvival RateTomography, X-Ray ComputedTreatment OutcomeVinblastineVincristine
2010
A breakthrough in Hodgkin's disease
DeVita V. A breakthrough in Hodgkin's disease. Nature Reviews Clinical Oncology 2010, 7: 179-179. PMID: 20354537, DOI: 10.1038/nrclinonc.2010.36.Peer-Reviewed Original Research
2008
More on strong inference
DeVita V. More on strong inference. Nature Reviews Clinical Oncology 2008, 5: 239-239. PMID: 18437157, DOI: 10.1038/ncponc1126.Peer-Reviewed Original ResearchStrong inference
DeVita V. Strong inference. Nature Reviews Clinical Oncology 2008, 5: 177-177. PMID: 18376422, DOI: 10.1038/ncponc1094.Peer-Reviewed Original Research
2005
The curse of the cure
DeVita V. The curse of the cure. Nature Reviews Clinical Oncology 2005, 2: 1-1. PMID: 16264829, DOI: 10.1038/ncponc0054.Peer-Reviewed Original Research
1999
The lymphomas.
DeVita V, Canellos G. The lymphomas. Seminars In Hematology 1999, 36: 84-94. PMID: 10595757.Peer-Reviewed Original ResearchHodgkin's disease and transplantation: a room with a (nontransplanter's) view.
Marshall N, DeVita V. Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. Seminars In Oncology 1999, 26: 67-73. PMID: 10073563.Peer-Reviewed Original ResearchConceptsHigh-dose chemotherapyPeripheral blood stem-cellHodgkin's diseaseOverall survivalRefractory diseaseDisease-freeBone marrowPeripheral blood stem-cell supportGraft-versus-host disease prophylaxisManagement of refractory diseasePatients potential candidatesImprove disease-freePatients disease-freeFollow-up timeShort follow-up timeResponse to treatmentSalvage chemotherapyApproach to treatmentCombination chemotherapyDose intensityTransplant supportAllograft patientsInitial remissionRelapse rateDisease prophylaxis
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptomsLate sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaNeoplasms, Second PrimaryRadiotherapyConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1994
Lymphomas.
Kwak L, DeVita V, Longo D. Lymphomas. 1994, 15: 413-70. PMID: 7779591.Peer-Reviewed Original Research
1993
Hodgkin's Disease
Wood A, DeVita V, Hubbard S. Hodgkin's Disease. New England Journal Of Medicine 1993, 328: 560-565. PMID: 8426624, DOI: 10.1056/nejm199302253280808.Peer-Reviewed Original ResearchLymphomas.
Kwak L, DeVita V, Longo D. Lymphomas. 1993, 14: 383-426. PMID: 8312110.Peer-Reviewed Original ResearchIs alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No.
DeVita V. Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No. Important Advances In Oncology 1993, 197-208. PMID: 8505053.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleHodgkin DiseaseHumans
1992
Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast.
Longo D, Duffey P, Hubbard S, Young R, DeVita V. Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast. Journal Of Clinical Oncology 1992, 10: 1367-9. PMID: 1634930, DOI: 10.1200/jco.1992.10.8.1367.Peer-Reviewed Original ResearchConventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptomsLymphomas.
Longo D, DeVita V. Lymphomas. 1992, 13: 349-403. PMID: 1389915.Peer-Reviewed Original ResearchThe use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Longo D, DeVita V. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. Important Advances In Oncology 1992, 155-65. PMID: 1582671.Peer-Reviewed Original Research
1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDiseaseTreatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal response